+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD267 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using CD267 mouse mAb (green) and negative control (red).    

  
  

CD267. also known as TACI (transmembrane activator and calcium-modulating cyclophilin ligand interactor), is a cell surface receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF13B). It is primarily expressed on B lymphocytes and plasma cells, playing a critical role in regulating humoral immunity. TACI interacts with ligands BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) to mediate signaling pathways involved in B-cell survival, differentiation, and antibody production. Dysregulation of TACI signaling is linked to immune disorders, including common variable immunodeficiency (CVID), systemic lupus erythematosus (SLE), and B-cell malignancies.

CD267 antibodies are tools used to study TACI's function or modulate its activity. As therapeutic agents, they may act as agonists or antagonists to either enhance immune responses (e.g., in immunodeficiency) or suppress pathogenic B-cell activity (e.g., in autoimmune diseases). Some monoclonal antibodies targeting TACI/BAFF/APRIL pathways have entered clinical trials for conditions like multiple myeloma or lupus. Additionally, CD267 antibodies serve as diagnostic markers in research to analyze receptor expression patterns in diseased tissues. Their dual role in immune activation and suppression makes them a focus for developing precision therapies balancing efficacy and safety in B-cell-related pathologies.